Walmart plans to offer more than 250 prescriptions at no cost to eligible employees in 2027, including some insulin products, inhalers and GLP-1 medicines for type 2 diabetes. The program applies to a workforce of about 1.6 million U.S. associates and is part of a broader benefits expansion ahead of open enrollment.
The retailer will cover Novo Nordisk's Ozempic and Eli Lilly's Mounjaro for employees with type 2 diabetes who meet a new prior-authorization requirement. It will not cover GLP-1 drugs when prescribed solely for weight loss. That boundary gives workers access to expensive diabetes treatment while limiting exposure to the much larger obesity market.
Benefits as a labor investment
Walmart is the largest private employer in the United States. Improving health benefits can support recruitment and retention, especially when other employers are raising premiums or reducing coverage. Walmart said the premium for its starting plan will rise by $1.50 per pay period to $39.80, a smaller increase than the prior year.
The company is also expanding access to second opinions from Mayo Clinic and Cleveland Clinic specialists for rare conditions. A separate paid leave benefit will provide up to 12 weeks for eligible parents whose newborn enters intensive care during the first 28 days after birth.
The financial trade-off is not disclosed
Walmart did not publish an expected cost for the prescription expansion. GLP-1 drugs are expensive, but prior authorization, diabetes-only eligibility and Walmart's purchasing scale can contain the bill. Better disease management could also reduce later medical claims and absenteeism, although the company has not quantified those savings.
The program's investor relevance is therefore operational. Richer benefits can reduce turnover and strengthen Walmart's position as an employer, but higher pharmacy and plan costs could pressure expenses if utilization rises faster than expected.
The useful measures will be enrollment, drug utilization, employee retention and Walmart's benefit cost per associate. Until management discloses those figures, the change should be read as a targeted workforce investment rather than a material earnings forecast. The design shows Walmart trying to broaden access while drawing a firm line around weight-loss coverage.